Clinical Trial Update: An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound [Phase 4]

View source ↗

Summary

Phase 4 trial of secukinumab in plaque psoriasis with subclinical psoriatic arthritis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 4 | Status: WITHDRAWN